
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bupivacaine
Therapeutic Area : Oncology
Study Phase : Phase II
Recipient : Nordic Nanovector
Deal Size : Undisclosed
Deal Type : Merger
Nordic Nanovector and APIM Therapeutics Announce Merger Agreement
Details : ATX-101 is a first-in-class peptide targeting PCNA (Proliferating Cell Nuclear Antigen), a master regulator of cellular responses to stress and in tumour cell evasion from therapy. ATX-101 is currently being evaluated in platinum-sensitive ovarian cancer...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 09, 2022
Lead Product(s) : Bupivacaine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Recipient : Nordic Nanovector
Deal Size : Undisclosed
Deal Type : Merger
